ReviewMolecular neurobiology2018
Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery?
Review in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.Clinical pharmacology and therapeutics · 2020Trial
- Hydrocephalus-associated persistent pain: a preclinical investigation correlating brain fluid imbalance and sensory alterations.Fluids and barriers of the CNS · 2026Article
- From the past to the present: evolving theories in the pathophysiology of normal pressure hydrocephalus.Journal of neurology, neurosurgery, and psychiatry · 2026Review
- Comparison ofMolecular therapy. Nucleic acids · 2025Article
- Cerebral Edema in Traumatic Brain Injury.Biomedicines · 2025Review
- A review of cerebrospinal fluid circulation with respect to Chiari-like malformation and syringomyelia in brachycephalic dogs.Fluids and barriers of the CNS · 2025Review
- Pre-clinical delivery of gene therapy products to the cerebrospinal fluid: challenges and considerations for clinical translation.Frontiers in molecular neuroscience · 2023Review
- Cerebrospinal fluid-tissue exchange revealed by phase alternate labeling with null recovery MRI.Magnetic resonance in medicine · 2022Article
- Single-Center Retrospective Analysis of Risk Factors for Hydrocephalus After Lateral Ventricular Tumor Resection.Frontiers in surgery · 2022Article
- Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery.Gene therapy · 2021Article
- The Need for Head Space: Brachycephaly and Cerebrospinal Fluid Disorders.Life (Basel, Switzerland) · 2021Review
- Antisense Drugs Make Sense for Neurological Diseases.Annual review of pharmacology and toxicology · 2021Review
- Recovery of motor function of chronic spinal cord injury by extracellular pyruvate kinase isoform M2 and the underlying mechanism.Scientific reports · 2020Article
- Polyplex transfection from intracerebroventricular delivery is not significantly affected by traumatic brain injury.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- GRP78-Mediated Signaling Contributes to Axonal Growth Resulting in Motor Function Recovery in Spinal Cord-Injured Mice.Frontiers in pharmacology · 2020Article
- Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension.Fluids and barriers of the CNS · 2019Review
- Current progress and challenges in the development of brain tissue models: How to grow up the changeable brain in vitro?Journal of tissue engineeringReview
- Leptomeningeal disease and tumor dissemination in a murine diffuse intrinsic pontine glioma model: implications for the study of the tumor-cerebrospinal fluid-ependymal microenvironment.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug delivery to the central nervous system (CNS) is complicated by the blood-brain barrier. As a result, many agents that are found to be potentially effective at their site of action cannot be sufficiently or effectively delivered to the CNS and therefore have been discarded and not developed further for clinical use, leaving many CNS diseases untreated. One way to overcome this obstacle is intracerebroventricular (ICV) delivery of the therapeutics directly to cerebrospinal fluid (CSF). Recent experimental and clinical findings reveal that CSF flows from the ventricles throughout the parenchyma towards the subarachnoid space also named minor CSF pathway, while earlier, it was suggested that only in pathological conditions such as hydrocephalus this form of CSF flow occurs. This transependymal flow of CSF provides a route to distribute ICV-infused drugs throughout the brain. More insight on transependymal CSF flow will direct more rational to ICV drug delivery and broaden its clinical indications in managing CNS diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.